Proactive Investors - Run By Investors For Investors

Kromek on course for EBITDA break-even this financial year

It was another period of good progress and upscaling in commercial activities with revenue growth driven by higher product sales in Kromek's key markets
DS3 nuclear radiation detection device
The D3S is the world's most advanced, portable, nuclear radiation detection device used by counter-terrorist agencies

Radiation technology company Kromek Group PLC (LON:KMK) saw a solid increase in revenue in the six months to the end of October.

Revenue rose 27% to £4.8mln from £3.8mln the year before, leading to a significant narrowing of underlying losses (Lbitda) to £0.3mln from a loss the year before of £0.6mln.

The company is targeting break-even at the Ebitda level and remains on course to achieve this.

READ: Kromek expects revenues to jump this year as demand continues to grow

Loss before tax was unchanged at £1.8mln.

At the end of the reporting period, the group had gross cash and cash equivalents of £15mln, down from £20.3mln at the beginning of the period.

“In the first half, we saw growth in sales through executing on our previously-signed agreements while, at the same time, continuing to win new high-value contracts,” said Arnab Basu, the chief executive officer of Kromek.

"We also succeeded in enhancing our reputation in our key target markets. Our D3S product was successfully deployed in high-profile situations for safeguarding against nuclear terrorism, and we achieved a significant milestone in SPECT by finalising the development of a system capable of producing clinical-grade images that will improve early stage diagnosis of diseases such as cancer and dementia,” he added.  

The group has entered the second half of the financial year in a good position to deliver revenue growth for the full-year and achieve EBITDA break-even, in line with market expectations.

READ: Kromek lands five-year contract worth at least US$5.38mln

“This position is underpinned by good visibility of revenues, with a significant proportion under signed contract. With our increasing traction with existing and potential customers, and with a strengthened order book, the board looks to the future with confidence," Basu said.

High-performance radiation detection

The results indicate that the Durham-headquartered group is reaping the rewards of two years’ worth of hard work during which it has been laying the foundations for future growth The £21mln fund-raising in February 2017, meanwhile, has given it the wherewithal to tap into the huge market opportunities and to invest in research and development, which keeps the company at the cutting edge of radiation technology.

The company is the developer of high-performance radiation detection products based on cadmium zinc telluride (CZT) and other advanced technologies.

Using its core platforms, Kromek designs, develops and produces x-ray and gamma photon imaging and radiation detection products for the medical, security screening and nuclear markets.

The products provide high-resolution information on material composition and structure. This means they can be used in many applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek operates a vertically integrated technology. What this means practically is it offers customers core technology components as well finished products such detectors, including software, electronics and application specific integrated circuits.

While based in the north-east, the business, which employs 100, has operations in California and Pennsylvania and sells internationally through distributors and direct to manufacturers.

Companies moving towards CZT technology

As Basu alluded to, the message from Kromek is that more and more companies are looking to move away from traditional detector technology to CZT.

Compared to the likes of silicon and germanium detectors, CZT operates at room temperature and can process more than 10mln photons / second / mm^2 (that’s a good thing).

“The unique combination of spectroscopy and very high count rate capability at room temperature makes CZT an ideal detector solution for Medical, Industrial, Homeland Security and Laboratory applications,” the Kromek website reads.

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

The Internet of Things
September 04 2018
"We have seen double-digit revenue growth, improved gross margins from H2 2017 and our cost optimisation plan is well underway," said Yosi Fait, Telit's CEO
scientist in lab
September 28 2018
Another of Amphion’s investee companies, Polarean Imaging, was floated on AIM earlier this year, and FireStar is the next one earmarked to go public
November 16 2018
The e-learning specialist upgraded its long-term goals to run-rate revenues of £200mln and run-rate underlying earnings of at least £55mln by 2021, an increase of around 100%

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use